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Abstract
Introduction Lung cancer is the leading cause of death by cancer. In recent years, immunotherapy with checkpoint inhibitors 
(ICI) emerged as a promising new therapeutic approach. However, a deeper understanding of the immunologic responses 
adjacent to the tumor known as tumor microenvironment (TME) is needed. Our study investigated TME of lung cancer by 
analyzing cytokines in bronchoalveolar lavage fluid (BALF).
Materials and methods Between January 2018 and June 2019, 119 patients were prospectively enrolled in this study. For 
each cancer patient, levels of 16 cytokines (fractalkine, granulocyte–macrophage colony-stimulating factor (GM-CSF), 
interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukins (IL): IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10, IL-12p70, IL-13, IL-17A, and IL-23) were measured in BALF and serum and compared to healthy individuals 
and patients with other lung diseases.
Results There were several significant differences of cytokine levels of patients with lung cancer compared to healthy 
individuals. However, none of them remained in the multivariate analysis compared to other lung diseases in either BALF 
or serum. Furthermore, there were no significant differences between the groups in cell differentiation of either BALF or 
serum. Cytokine levels in BALF were generally near the lower detection limit and showed almost no correlation with their 
respective levels measured in serum of the same individual.
Conclusions Cytokines in BALF and serum of lung cancer patients may indicate unspecific inflammation. BAL is not recom-
mendable as a tool to investigate TME of lung cancer. Therefore, cytokines measured in BALF are probably not appropriate 
as predictors in patients treated with ICIs.
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TME  Tumor microenvironment
TNF-α  Tumor necrosis factor alpha
Introduction
Lung cancer is the most common type of cancer worldwide 
and with 1.8 million reported cases of death in 2018 the 
leading cause of death by cancer in both men and women 
[1]. Its high lethality is mainly attributed to late appear-
ance of symptoms leading to detection in already advanced 
tumor stages when curative treatment is usually no longer 
possible. In recent years, immunotherapy with checkpoint 
inhibitors (ICI) emerged as a promising new therapeutic 
approach in advanced or metastasized tumor stages, which 
may be able to revolutionize modern anticancer treatment 
[2, 3]. However, to develop new ICI or to choose the most 
promising ICI for a specific cancer phenotype, a deeper 
understanding of the immunologic responses adjacent to 
the tumor is needed. This so-called tumor microenviron-
ment (TME) is formed by cancer cells, immune cells, stro-
mal cells, and cytokines. Cytokines are immunomodulatory 
proteins, which are expressed by a variety of cells ranging 
from immune cells like macrophages and lymphocytes to 
endothelial cells and fibroblasts. During inflammation, they 
act as communicators between immune cells for regulat-
ing cell growth, maturation, and responsiveness [4, 5]. As 
recent data suggest a higher response rate to ICIs in “hot” or 
"active" tumors defined by immunological activation of the 
TME, there have been several trials trying to find biomarkers 
for either diagnosis or patient selection for ICI. However, so 
far, only the expression of programmed cell death ligand-1 
(PD-L1) on cancer cells as well as a high tumor mutational 
burden has been found to show a positive predictive value 
for the efficacy of either PD-1 or PD-L1 inhibitors [6–12].
Bronchoalveolar lavage (BAL) is a sample technique 
of flexible bronchoscopy, which obtains liquid biopsy by 
flooding and subsequent aspiration of normal saline from 
the investigated lung segment or subsegment. The recov-
ered fluid sample physiologically contains inflammatory 
cells and potentially tumor cells for cytological diagnos-
tics. In addition, several biochemical elements acting as 
possible biomarkers may possibly be detected in BAL fluid 
(BALF). Although BAL drains a relatively large area sur-
rounding a lung tumor and, therefore, the diagnostic yield 
is hypothetically not dependent on a bronchus leading to it, 
the diagnostic usefulness of BAL is unacceptably low with 
a reported sensitivity for the diagnosis of lung cancer of 
29% when only cytological analyses are considered [13]. 
However, with the upcoming interest in ICIs, BAL gained 
new attention as a tool to access TME surrounding a lung 
cancer [14–23]. With our study, we aimed to investigate 
TME of lung cancer by analyzing various cytokines in 
BALF and thus answering three questions:
1.  Are there certain cytokines, which are upregulated in 
lung cancer patients compared to healthy individuals and 
to patients with other lung diseases?
2.  Does the local immunological response (measured in 
BALF) have a correlation with the systemic immuno-
logical response (measured in blood serum)?




This study is part of a prospective multicenter study aimed 
to establish a biobank (“BALOTHEK”) containing BALF 
and blood serum for the investigation of various lung dis-
eases in patients in whom BAL was indicated as part of 
their routine clinical evaluation. Enrolled patients were 
retrospectively grouped according to their final diagnosis 
as confirmed by histology and finally allocated into four 
groups describing different lung diseases: lung cancer, sar-
coidosis, interstitial lung disease (ILD), and drug-related 
pneumonitis. A fifth group consisted of patients who 
underwent bronchoscopy for assessment of chronic cough 
with a normal chest computed tomography (CT) finding 
(i.e., absence of consolidation, ground-glass opacity, nod-
ule, mass, or interstitial changes) and without evidence 
of lung disease during a follow-up time of six months. 
Thus, the latter group served as healthy control group with 
structural normal lung parenchyma. Exclusion criteria for 
enrollment in BALOTHEK were history of lung transplan-
tation, patient vulnerability such as pregnancy or emer-
gency setting, as well as possible sampling and processing 
failures, such as a low BALF recovery rate resulting in 
less than 10 ml of BALF for the purpose of the biobank 
or a BAL-to-processing time exceeding 1 h as described 
elsewhere [24].
Between January 2018 and June 2019, a total of 401 adult 
patients were prospectively enrolled in the BALOTHEK. 
After exclusion of patients with conditions possibly influ-
encing the cytokine levels (infection, systemic immunosup-
pressants including systemic corticosteroids, and alveolar 
hemorrhage), uncertain diagnosis or malignancy other than 
lung cancer, and sampling/processing failures, 119 patients 
were included for the purpose of this study (Fig. 1).
All patient-related data including demographic and clini-
cal data as well as bronchoscopy, radiology, and pathology 
reports were drawn from patient record files.
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Bronchoscopy and BAL technique
All patients underwent FB using Olympus (Olympus, Tokyo, 
Japan) bronchoscopes (190 series) under moderate sedation 
using propofol or general anesthesia according to the clini-
cian’s decision. BAL was performed following the standard-
ized procedure described by Baughman by injecting four 
portions of 50 ml (200 ml in total) of isotonic normal saline 
into the wedged segmental bronchus leading to the target 
lesion with the most prominent radiological finding [25]. 
BALF was recovered by gentle suction with the same syringe 
and collected in a graduated plastic cylinder. Approximately 
50 ml of BALF was reserved for routine clinical analyses; 
excess fluid was used for the purpose of BALOTHEK.
Processing of BAL fluid and blood specimens
BALF was collected in plastic tubes and centrifuged at 
1′000 rounds per minute for 10 min at room temperature. 
The supernatant was collected and stored at − 80 °C for later 
analyses. The aliquots were only thawed once for analy-
sis to prevent falsification of cytokine levels by repeated 
freezing and thawing. The routinely performed analysis of 
BALF for cell differentiation was performed by ADVIA 
2120i (Siemens Healthcare AG, Zurich, Switzerland) via 
peroxidase staining. Cell differentiation included cell count, 
macrophages, lymphocytes, neutrophils, eosinophils, mast 
cells, and plasma cells. Blood samples were drawn as part 
of the routinely performed pre-interventional peripheral vein 
access. Whole blood was collected in a 10-ml BD Vacutainer 
Clot Activator Tube (CAT, Plus Blood Collection Tubes, 
Becton Dickinson, Plymouth, UK) and centrifuged at 3′500 
rounds per minute for 10 min at room temperature. The sub-
sequent process was analogous to the handling of BALF.
Selection of cytokines
We specifically selected cytokines which were verified in 
previous studies as factors in TME of lung cancer, serv-
ing as rationale for their use in this study. Fractalkine is a 
prohibiting factor for metastasis and has a particularly high 
expression in the lungs [26]. Granulocyte–macrophage col-
ony-stimulating factor (GM-CSF) can act pro-inflammatory 
as well as anti-inflammatory depending on the concentration 
and its environment [27, 28]. When secreted by tumor cells 
themselves, GM-CSF may lead to immune evasion for the 
tumor by promoting the development of myeloid suppressor 
cells [29]. Interferon gamma (IFN-γ) has been shown to be 
downregulated in progressive tumor disease as a sign for 
lower expression by natural killer cells [30]. Tumor necrosis 
factor alpha (TNF-α) is a marker for alveolar macrophage 
activity and plays a role in inhibiting carcinogenesis as 
well as angiogenesis [31]. Notably, it has been shown to 
be increased in exhaled breath condensate in patients with 
Fig. 1  Selection of study 
population
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NSCLC in a previous study [32]. Interleukin (IL) 1b and 
IL-6 also act as markers for alveolar macrophage activity, 
and have been shown to be increased in BALF of lung cancer 
patients, with increase of IL-1b acting as a positive prognos-
tic factor and increase of IL-6 acting as a negative prognostic 
factor for survival in lung cancer [33–35]. IL-2 has a strong 
effect on activation of natural killer cells [36]. Furthermore, 
it has been shown to be increased in exhaled breath con-
densate in patients with NSCLC [32]. IL-4 and IL-13 have 
been shown to have higher histopathological expressions of 
NSCLC in a previous study [37]. IL-5 had been shown to 
have an augmenting role in metastasis in lung cancer in mice 
models [38]. IL-7 has been shown to have an anti-apoptotic 
and thus pro-carcinogenic effect on lung cancer cells [39]. 
IL-8 is a chemoattractant for various immune cells as well 
as an inducer of angiogenesis [4]. Elevated levels of IL-8 
have been shown to predict decreased survival in lung can-
cer [35]. Furthermore, rapid decrease of IL-8 levels dur-
ing anti-PD-1 treatment correlated with treatment success 
[40]. IL-10 has an immunosuppressive effect and has been 
shown to be expressed by alveolar macrophages in TME of 
primary lung cancer. Increased levels of IL-10 positively 
correlated with tumor progression (size, metastasis, and poor 
histologic differentiation) [41]. IL-12 and in its activated 
form IL-12p70 are activators of natural killer cells as well 
as alveolar macrophages [4]. In mice models, knock-out of 
IL-12 induced spontaneous development of lung carcinomas 
[42]. Additionally, IL-12 and IFN-γ act as necessary media-
tors of anti-PD-1 treatment [43]. IL-13 is a marker of natural 
killer cell activity and been shown to be associated with 
progression and metastasis of lung cancer [44, 45]. IL-17 is 
a promotor of angiogenesis and cell proliferation as well as 
an inhibitor of apoptosis. As such, IL-17 has been shown to 
have a correlation with tumor progression and metastasis of 
lung cancer [46]. IL-23 suppresses the activity of B cells, T 
cells, and natural killer cells and thus promotes tumor pro-
gression and metastasis in lung cancer [30, 47].
Cytokine analysis
The cytokine analysis was conducted using a cytokine 
multiple array on a Luminex 200 platform (Luminex 
Corporation, Austin, TX, USA) with a high sensitivity 
Milliplex kit (HSTCMAG-28SK-10, Merck Millipore, 
Darmstadt, Germany). The array included the following 
cytokines: fractalkine, granulocyte–macrophage colony-
stimulating factor (GM-CSF), interferon gamma (IFN-γ), 
tumor necrosis factor alpha (TNF-α), and several inter-
leukins (IL): IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, 
IL-10, IL-12p70, IL-13, IL-17A, and IL-23. The accept-
ance criteria included the % coefficient of variation of the 
intra-assay, inter-assay, and replicates of low concentrated 
BALF, as well as the lower limit of detection, the lower 
limit of quantification, and the linearity.
Statistical analysis
Levels of each cytokine of the case group (lung cancer) 
were analyzed against two control groups consisting of 
healthy individuals and patients with other lung diseases 
(sarcoidosis and ILD).
All statistical analyses were performed using SPSS 
Statistics for Windows 22.0 (IBM, Armonk, NY, USA). 
Normal distribution was assessed by the Kolmogo-
rov–Smirnoff test. As all data were not normally dis-
tributed, data are reported as median ± interquartile 
range (IQR) or as percentages, as appropriate. Test for 
likeness was conducted by Pearson Correlation. Differ-
ences of means between the cohorts were calculated by 
Mann–Whitney U Test. Variables with p value < 0.1 were 
entered into a multivariate regression model. Minimum 
power level was set at 0.8. [48] The confidence interval 
(CI) was defined as 95%. p values of all outcomes were 
two-sided; a value less than 0.05 was considered statisti-
cally significant.
As the complete array of cytokines was analyzed in 
every patient, measurements of cytokine concentration 
with a median of 0.00 do neither imply an analytical error 
in cytokine measurement nor a reduction of patient samples 
but rather a cytokine concentration below the measurable 
detection limit in vivo, which in itself was considered an 
important finding. Consequently, we included all results in 




In total, 119 patients were included in this study. We split 
the study population into three groups: a first group with 
53 patients with lung cancer (44.5%), a second group with 
32 healthy individuals (26.9%), and a third group with 34 
patients with other lung diseases (28.5%) consisting of 28 
patients with sarcoidosis (23.5%) and six patients with ILD 
(5.0%). Baseline characteristics for each group are shown 
in Table 1. There were significant differences in age, pack 
years, smoking status, and BALF recovery rate. However, 
there were no significant differences between the groups in 
cell differentiation of either BALF or serum.
Tumor-specific characteristics of the lung cancer group 
are shown in Table 2.
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Correlation of cytokines in BALF and serum
Statistical analysis of cytokine levels found in BALF com-
pared to cytokine levels found in serum of all patients 
showed significant correlations only for IL-1b, as shown in 
Table 3.
Cytokines in BALF
The cytokine levels in BALF of lung cancer patients com-
pared to both healthy individuals and patients with other 
lung diseases are shown in Table 4. According to uni-
variate analysis, there were several significant differences 
in cytokine levels between both groups. As such, there 
was a striking increase of IL-8 in the lung cancer group 
(p = 0.002). However, after correction for co-factors (age, 
pack years, smoking status, and BALF recovery rate), none 
of the cytokines (including IL-8) showed statistically signifi-
cant differences between the two groups. When subgroups 
were compared, multivariate analysis revealed significantly 
higher IL-8 levels in lung cancer patients compared to 
healthy subjects (p = 0.029) but not compared to patients 
with other lung diseases (p = 0.921) (data not shown). The 
subgroup analysis of different types of lung cancer and other 
characteristics listed in Table 2 showed no significant asso-
ciations with cytokine levels in BALF.
Table 2  Characteristics of lung cancer group
Data are presented as n (%) or median (IQR)
NSCLC non-small cell lung cancer, SCLC small cell lung cancer, 
SUVmax maximum standardized uptake value
Type
 Adenocarcinoma 34 (64.2)


















 Maximum diameter, mm 30.0 (18.0–46.0)
 Tumor > 2 cm 40 (75.5)
 SUVmax 9.6 (5.4–14.8)
Table 3  Correlation of cytokine 
levels in BALF compared to 
serum in all patients (n = 119)
* = p < 0.05. Data are presented in median (IQR), cytokine levels in pg/ml
BALF bronchoalveolar lavage fluid, GM-CSF granulocyte–macrophage colony-stimulating factor, IFN-γ 
interferon gamma, IL interleukin, TNF-α tumor necrosis factor alpha
Cytokine BALF Serum p value Pearson correla-
tion coefficient r
Fractalkine 30.90 (0.00–77.81) 189.40 (131.84–282.94) 0.487 − 0.065
GM-CSF 6.97 (3.45–13.95) 25.72 (10.54–66.02) 0.357 0.086
IFN-γ 0.09 (0.00–0.27) 11.43 (4.91–23.14) 0.686 0.038
IL-1b 0.31 (0.23–0.57) 1.84 (0.36–3.14) 0.001* 0.303
IL-2 1.05 (0.53–1.92) 3.21 (1.53–5.61) 0.990 0.001
IL-4 0.00 (0.00–0.00) 22.16 (9.48–45.90) 0.425 − 0.075
IL-5 0.19 (0.12–0.31) 3.82 (2.25–5.69) 0.059 0.176
IL-6 1.12 (0.59–3.29) 4.74 (2.52–8.74) 0.635 0.044
IL-7 5.36 (2.15–11.11) 12.44 (9.62–18.43) 0.860 − 0.017
IL-8 33.34 (13.35–68.26) 10.60 (7.24–18.17) 0.500 0.063
Il-10 1.23 (0.36–3.27) 9.72 (5.38–14.90) 0.877 0.015
IL-12b 0.00 (0.00–0.05) 3.51 (1.60–6.65) 0.685 − 0.038
IL-13 0.00 (0.00–0.59) 5.39 (1.80–10.76) 0.570 − 0.053
IL-17a 0.22 (0.22–0.38) 11.82 (4.60–24.17) 0.708 0.035
IL-23 1.49 (0.00–3.48) 271.09 (142.92–492.15) 0.491 − 0.065
TNF-α 0.71 (0.31–1.47) 10.40 (5.71–14.46) 0.211 0.117
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Cytokine levels in serum
The cytokine levels in serum for patients with lung cancer 
compared to both healthy individuals and patients with 
other lung diseases are shown in Table 5. After correction 
for co-factors (age, pack years, smoking status, and BALF 
recovery rate), statistically significant increases of frac-
talkine, GM-CSF, IFN-γ, IL-1b, IL- 4, IL-8, IL-17a, 
IL-23, and TNF-α remained.
Table 4  Cytokine levels in 
BALF of lung cancer patients 
compared to both healthy 
individuals and patients with 
other lung diseases
* = p < 0.05. Data are presented in median (IQR), cytokine levels in pg/ml
BALF bronchoalveolar lavage fluid, GM-CSF granulocyte–macrophage colony-stimulating factor, IFN-γ 
interferon gamma, IL interleukin, TNF-α tumor necrosis factor alpha





Fractalkine 19.53 (0.00–103.24) 37.02 (0.00–68.60) 0.615 0.518
GM-CSF 6.11 (0.30–18.82) 6.97 (4.08–11.72) 0.709 0.114
IFN-γ 0.09 (0.01–0.25) 0.01 (0.00–0.57) 0.543 0.762
IL-1b 0.37 (0.28–0.58) 0.28 (0.08–0.57) 0.006* 0.841
IL-2 1.47 (0.86–2.16) 0.75 (0.18–1.38) < 0.001* 0.358
IL-4 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.019* 0.434
IL-5 0.19 (0.16–0.28) 0.19 (0.00–0.66) 0.396 0.389
IL-6 1.41 (0.64–5.30) 0.98 (0.53–2.52) 0.445 0.699
IL-7 4.18 (0.80–9.09) 6.94 (3.50–12.65) 0.006* 0.261
IL-8 48.85 (16.85–114.12) 17.71 (8.26–51.36) 0.002* 0.910
Il-10 0.78 (0.40–2.14) 1.98 (0.36–4.68) 0.317 0.596
IL-12b 0.04 (0.00–0.08) 0.00 (0.00–0.03) < 0.001* 0.781
IL-13 0.00 (0.00–0.33) 0.24 (0.00–0.69) 0.048* 0.285
IL-17a 0.22 (0.22–0.22) 0.27 (0.22–0.73) < 0.001* 0.309
IL-23 1.49 (0.00–1.49) 1.49 (0.00–21.44) 0.139 0.782
TNF-α 0.64 (0.14–1.28) 0.76 (0.42–1.63) 0.133 0.928
Table 5  Cytokine levels in 
serum in lung cancer patients 
compared to both healthy 
individuals and patients with 
other lung diseases
* = p < 0.05. Data are presented in median (IQR). Cytokine levels are denoted in pg/ml
BALF bronchoalveolar lavage fluid, GM-CSF granulocyte–macrophage colony-stimulating factor, IFN-γ 
interferon gamma, IL interleukin, TNF-α tumor necrosis factor alpha






Fractalkine 239.28 (183.11–304.15) 149.85 (102.90–239.22) < 0.001* 0.006*
GM-CSF 53.98 (35.04–70.93) 13.13 (8.17–22.30) < 0.001* 0.009*
IFN-γ 17.30 (10.08–32.89) 8.53 (3.51–19.88) < 0.001* 0.028*
IL-1b 2.86 (1.95–4.00) 0.43 (0.23–1.92) < 0.001* < 0.001*
IL-2 4.52 (2.35–6.61) 1.85 (1.37–4.58) 0.001* 0.170
IL-4 38.45 (23.79–52.58) 12.20 (6.07–22.89) < 0.001* 0.002*
IL-5 3.86 (2.44–5.65) 3.57 (2.25–5.78) 0.743 0.970
IL-6 6.28 (3.80–9.13) 3.22 (1.68–6.46) < 0.001* 0.685
IL-7 15.15 (10.20–19.34) 12.10 (8.84–17.50) 0.117 0.733
IL-8 14.08 (9.76–20.82) 8.18 (6.54–14.76) < 0.001* 0.018*
Il-10 11.72 (8.33–17.09) 8.30 (2.46–13.81) 0.003* 0.766
IL-12b 4.99 (3.27–8.33) 2.41 (1.24–4.45) < 0.001* 0.676
IL-13 8.90 (4.18–13.38) 2.98 (1.28–7.74) < 0.001* 0.713
IL-17a 16.19 (10.29–32.45) 6.80 (1.92–16.58) < 0.001* 0.003*
IL-23 412.70 (203.21–741.72) 215.83 (101.15–383.18) 0.001* 0.006*
TNF-α 12.40 (10.40–16.58) 7.10 (3.71–11.46) < 0.001* 0.033*
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To differentiate between unspecific activation of the 
immune system and cancer-specific elevation of cytokine 
levels, multivariate analysis was repeated with separated 
control groups as seen in ESM Tables 6 and 7. Table 6 
shows cytokine levels in serum in patients with lung cancer 
compared to healthy individuals. After correction for co-
factors (age, pack years, smoking status, and BALF recov-
ery rate), statistically significant elevations for fractalkine, 
GM-CSF, IFN-γ, IL-1b, IL-2, IL- 4, IL-8, IL-12b, IL-17a, 
IL-23, and TNF-α remained. In contrast, there was no statis-
tically significant difference of any cytokine in lung cancer 
patients compared to patients with other lung diseases (ESM 
Table 7).
Notably, multivariate analysis of cytokine levels in 
patients with other lung diseases compared to cytokine 
levels in healthy individuals showed similar findings as the 
lung cancer group with statistically significant elevations for 
IL-1b (p = 0.016), IL-4 (p = 0.017), and TNF-α (p = 0.004) 
as well as a trend towards elevated levels for fractalkine 
(p = 0.067), GM-CSF (p = 0.073), IL-2 (p = 0.076), and 
IL-23 (p = 0.073) (not shown in table).
Discussion
The primary goal of our study was to investigate whether 
certain cytokines are locally (BALF) or systemically (serum) 
upregulated in patients with lung cancer compared to healthy 
subjects or to patients with other lung diseases. Possibly 
owed to a lack of correlation between cytokines measured in 
BALF compared to those measured in the serum, we found 
that several cytokines in the serum of lung cancer patients 
were significantly increased compared to healthy controls, 
but not in BALF. Furthermore, our study was not able to 
detect a statistically significant increase of any cytokine in 
either BALF or serum in patients with lung cancer compared 
to patients with other lung diseases. Thus, the investigated 
cytokines were only able to indicate unspecific activation 
of the immune system rather than a differentiation between 
entities. Notably, there was an insignificant, but striking 
increase of IL-8 in BALF in lung cancer patients. This 
increase might be linked to the role of IL-8 in angiogenesis 
in addition to its role in the immunological response [49].
The secondary goal of our study was to investigate 
whether there is a correlation between the local immuno-
logical response in BALF and the systemic immunologi-
cal response in blood serum. The majority of the investi-
gated cytokines showed no significant correlation between 
cytokine levels measured in BALF compared to cytokine 
levels in serum of the same individual. This weak correla-
tion of cytokines in BALF and serum is partly explained 
by diluted concentrations in BALF, which was previously 
described by our group [24]. However, our data suggest that 
local and systemic immunological responses do not neces-
sarily correspond.
The tertiary goal of our study was to investigate cytokines 
in TME as assessed by BAL. Due to the inevitable dilution 
during BAL, the cytokine levels in BALF were generally 
near the lower detection limit, which may be associated with 
lower accuracy of the essay. Thus, the dilution may pose a 
limitation for BAL as a tool for analysis of TME. Certainly, 
a current topic of interest in oncology is the investigation 
on predictors of ICIs. However, most patients in our study 
received several, not study-controlled forms of cancer ther-
apy, rendering the available data invalid for statistical analy-
sis. Thus, further studies for the evaluation of cytokines as 
prognostic markers for ICIs are needed. However, according 
to the present study, we cannot recommend BALF as vehicle 
for corresponding cytokine analyses.
The second control group consisting of other lung dis-
eases was inherently heterogenous and thus not eligible 
for a deduction of conclusions as a target of investigation 
itself. However, we included the data to put the findings of 
the analysis between the lung cancer group and the healthy 
control group into perspective, as almost all similar stud-
ies lacked such comparison. This allowed us to approxima-
tively differentiate between unspecific cytokine increase due 
to generalized immunological response and tumor-specific 
and subsequently clinically relevant cytokine increase.
The limitation of this study was the number of cases used 
for statistical analysis, as it was not high enough to conduct a 
subgroup analysis for different types of cancers (e.g., small 
cell lung cancer). At the same time, we were able to ensure 
a high quality in patient selection by applying strict exclu-
sion criteria.
Furthermore, this study was not designed to evaluate the 
prognostic value of cytokines. Consequently, survival was 
greatly influenced by the patient’s and treating physician’s 
decision for or against various treatment options. Therefore, 
survival as a parameter for prognostic value of cytokine lev-
els was not subject of the study.
Conclusion
Cytokines in BALF and serum of lung cancer patients may 
indicate unspecific inflammation. BAL is not recommend-
able as a tool to investigate TME of lung cancer. Therefore, 
cytokines measured in BALF are probably not appropriate 
as predictors in patients treated with ICIs.
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